Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks

References

• GoodinDSFrohmanEMGarmanyGPJrTherapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesDisease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesNeurology200258216917811805241
   PubMed Web of Science ®Google Scholar
• EinarsonTRBerezaBGMachadoMComparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studiesCurr Med Res Opin201733357959328027680
   PubMed Web of Science ®Google Scholar
• HuXShangSNestorovICOMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjectsBr J Clin Pharmacol201682238038827060836
   PubMed Web of Science ®Google Scholar
• CalabresiPAKieseierBCArnoldDLPegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind studyLancet Neurol201413765766524794721
   PubMed Web of Science ®Google Scholar
• KieseierBCArnoldDLBalcerLJPeginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCEMultScler201521810251035
   Google Scholar
• NaismithRTHendinBWraySYouXSabatellaGZambranoJALLOW a phase 3b trial characterising flu-like symptoms in patients transitioning to pegylated interferon beta1a: interim analysis of all patientsPoster presented at: 31th Congress of the European Committee for Treatment and Research in Multiple SclerosisOctober 7–10, 2015Barcelona, SpainP1114
   Google Scholar
• NaismithRTHendinBWraySHuangDYouXWerneburgBLow risk of new flu-like symptoms in patients transitioning from non-pegylated to pegylated interferon beta-1a and mitigation with scheduled naproxenPoster presented at: Consortium of Multiple Sclerosis Centers 2016 Annual MeetingJune 1–4, 2016National Harbor, MD, USAP-SX12
   Google Scholar
• BrodyDSMillerSMLermanCESmithDGCaputoGCPatient perception of involvement in medical care: relationship to illness attitudes and outcomesJ Gen Intern Med1989465065112585158
   PubMed Web of Science ®Google Scholar
• BarbosaCDBalpMMKulichKGermainNRofailDA literature review to explore the link between treatment satisfaction and adherence, compliance, and persistencePatient Prefer Adherence20126394822272068
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJ Manag Care Pharm2013191 Suppl AS24S4023383731
   PubMed Web of Science ®Google Scholar
• PattiFOptimizing the benefit of multiple sclerosis therapy: the importance of treatment adherencePatient Prefer Adherence201041920165593
   PubMed Web of Science ®Google Scholar
• VermerschPHobartJDive-PoulettyCBozziSHassSCoylePKMeasuring treatment satisfaction in MS: is the Treatment Satisfaction Questionnaire for Medication fit for purpose?MultScler2017234604613
   Google Scholar
• AtkinsonMJSinhaAHassSLValidation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic diseaseHealth Qual Life Outcomes200421214987333
   PubMedGoogle Scholar
• TingJLiuYPetrilloJGiannattasioGSabatellaGTreatment satisfaction with disease modifying therapies in multiple sclerosis: a systematic review of studies using the Treatment Satisfaction Questionnaire for Medication (TSQM)Value Health2015187A760A761
   Web of Science ®Google Scholar
• RegnaultABalpMMKulichKViala-DantenMValidation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosisJ Cyst Fibros201211649450122583743
   PubMed Web of Science ®Google Scholar
• BeerKMüllerMHew-WinzelerAMThe prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBMC Neurol20111114422074056
   PubMed Web of Science ®Google Scholar
• VermerschPCzlonkowskaAGrimaldiLMTENERE Trial GroupTeriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trialMult Scler201420670571624126064
   PubMed Web of Science ®Google Scholar
• FoxEJEdwardsKBurchGEPOC study investigatorsOutcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosisMultScler Relat Disord201435607619
   PubMed Web of Science ®Google Scholar
• HaaseRKullmannJSZiemssenTTherapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS surveyTher Adv Neurol Disord20169425026327366231
   PubMed Web of Science ®Google Scholar
• GlanzBIMusallamARintellDJChitnisTWeinerHLHealyBCTreatment satisfaction in multiple sclerosisInt J MS Care2014162687525061430
   PubMedGoogle Scholar
• RossAPTolerability, adherence, and patient outcomesNeurology20087124 Suppl 3S21S2319064871
   PubMed Web of Science ®Google Scholar
• VisserLHvan der ZandeAReasons patients give to use or not to use immunomodulating agents for multiple sclerosisEur J Neurol201118111343134921496180
   PubMed Web of Science ®Google Scholar
• KapposLKuhleJMultanenJFactors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15J Neurol Neurosurg Psychiatry201586111202120726374702
   PubMed Web of Science ®Google Scholar